STOCK TITAN

[144] Cardlytics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Cardlytics, Inc. (CDLX) Form 144 notice shows an insider intends to sell 8,493 shares of common stock, with an aggregate market value of $19,286.75, on or about 10/02/2025 through Fidelity Brokerage Services LLC on NASDAQ. The shares were acquired on 10/01/2025 by restricted stock vesting as compensation. The filer also reported two prior sales in the past three months: 7,324 shares sold on 07/02/2025 for $13,055.76 and 26,048 shares sold on 08/15/2025 for $31,695.21. The filer certifies no undisclosed material adverse information is known.

Cardlytics, Inc. (CDLX) l'avviso del Form 144 mostra che un insider intende vendere 8.493 azioni ordinarie, con un valore di mercato aggregato di $19.286,75, approssimativamente il 02/10/2025 tramite Fidelity Brokerage Services LLC su NASDAQ. Le azioni sono state acquisite il 01/10/2025 tramite vesting di azioni restritte come compenso. Il dichiarante ha inoltre riportato due vendite precedenti negli ultimi tre mesi: 7.324 azioni vendute il 02/07/2025 per $13.055,76 e 26.048 azioni vendute l'15/08/2025 per $31.695,21. Il dichiarante certifica che non è noto alcuna informazione materiale avversa non disclosure.

Cardlytics, Inc. (CDLX) el aviso del Formulario 144 indica que un insider tiene la intención de vender 8,493 acciones comunes, con un valor de mercado agregado de $19,286.75, alrededor del 02/10/2025 a través de Fidelity Brokerage Services LLC en NASDAQ. Las acciones fueron adquiridas el 01/10/2025 por vesting de acciones restringidas como compensación. El presentante también reportó dos ventas previas en los últimos tres meses: 7,324 acciones vendidas el 02/07/2025 por $13,055.76 y 26,048 acciones vendidas el 15/08/2025 por $31,695.21. El presentante certifica que no se conoce información material adversa no revelada.

Cardlytics, Inc. (CDLX) Form 144 공지에 따르면 내부자가 8,493 주의 보통주를 $19,286.75의 총 시장가치로, 대략 2025년 10월 2일Fidelity Brokerage Services LLC를 통해 NASDAQ에서 매도하려는 의도를 가지고 있습니다. 이 주식은 2025년 10월 1일restricted stock vesting으로 보상으로 취득되었습니다. 신고자는 지난 3개월 동안 두 건의 이전 매도도 보고했습니다: 7,324 주가 2025년 7월 2일$13,055.76에 매도되었고, 26,048 주가 2025년 8월 15일$31,695.21에 매도되었습니다. 신고자는 공개되지 않은 중요한 악재 정보가 없다고 인증합니다.

Cardlytics, Inc. (CDLX) l'avis Form 144 indique qu'un initié a l'intention de vendre 8 493 actions ordinaires, d'une valeur marchande totale de $19 286,75, vers le 02/10/2025, par Fidelity Brokerage Services LLC, sur le NASDAQ. Les actions ont été acquises le 01/10/2025 par vesting d'actions restreintes en tant que rémunération. Le déclarant a également signalé deux ventes antérieures au cours des trois derniers mois : 7 324 actions vendues le 02/07/2025 pour $13 055,76 et 26 048 actions vendues le 15/08/2025 pour $31 695,21. Le déclarant certifie qu'aucune information matérielle adverse non divulgée n'est connue.

Cardlytics, Inc. (CDLX) Form 144 Hinweis zeigt, dass ein Insider beabsichtigt, 8.493 Stammaktien zu verkaufen, mit einem Gesamtmarktwert von $19.286,75, ungefähr am 02.10.2025 über Fidelity Brokerage Services LLC an der NASDAQ. Die Aktien wurden am 01.10.2025 durch Restricted Stock Vesting als Vergütung erworben. Der Einreicher meldete außerdem zwei vorherige Verkäufe in den letzten drei Monaten: 7.324 Aktien am 02.07.2025 für $13.055,76 und 26.048 Aktien am 15.08.2025 für $31.695,21. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

Cardlytics, Inc. (CDLX) يظهر إشعار النموذج 144 أن داخلًا يعتزم بيع 8,493 سهمًا من الأسهم العادية، بقيمة سوقية إجمالية قدرها $19,286.75، في أو نحو 02/10/2025 من خلال Fidelity Brokerage Services LLC في ناسداك. تم اكتساب الأسهم في 01/10/2025 بواسطة vesting stock مقيد كـ تعويض. كما أبلغ المقدّم عن عمليتين بيع سابقتين في الأشهر الثلاثة الماضية: 7,324 سهمًا بُيع في 02/07/2025 بمبلغ $13,055.76 و 26,048 سهمًا بُيع في 15/08/2025 بمبلغ $31,695.21. يُقر المقدم بأنه لا يوجد معلومات سلبية جوهرية غير معلنة معروفة.

Cardlytics, Inc. (CDLX) 的 Form 144 通知显示,一名内部人士打算在 2025-10-02 通过 Fidelity Brokerage Services LLC 在 NASDAQ 出售 8,493 股普通股,市值总额约为 $19,286.75。这些股票是在 2025-10-01restricted stock vesting 作为 补偿 而取得。这位申报人还报告了过去三个月内的两笔先前出售:在 2025-07-02 出售 7,324 股,成交价为 $13,055.76,以及在 2025-08-15 出售 26,048 股,成交价为 $31,695.21。申报人证明没有未披露的重大不利信息。

Positive
  • 8,493 shares acquired by restricted stock vesting, indicating compensation rather than open-market purchase
  • Sale will be executed through Fidelity Brokerage Services LLC on the NASDAQ, a regulated venue
Negative
  • Insider proposes sale of 8,493 shares with aggregate market value $19,286.75, increasing insider supply
  • Two prior sales in last three months totaling 33,372 shares were reported, potentially increasing sell-side pressure

Insights

Insider plans to sell recently vested 8,493 shares on 10/02/2025.

The filing states the 8,493 shares were acquired on 10/01/2025 through restricted stock vesting and are to be sold for an aggregate market value of $19,286.75 via Fidelity Brokerage Services LLC on NASDAQ.

The Form 144 also discloses two earlier sales by the same person in the past three months: 7,324 shares on 07/02/2025 for $13,055.76 and 26,048 shares on 08/15/2025 for $31,695.21, which are reported in the filing.

Cardlytics, Inc. (CDLX) l'avviso del Form 144 mostra che un insider intende vendere 8.493 azioni ordinarie, con un valore di mercato aggregato di $19.286,75, approssimativamente il 02/10/2025 tramite Fidelity Brokerage Services LLC su NASDAQ. Le azioni sono state acquisite il 01/10/2025 tramite vesting di azioni restritte come compenso. Il dichiarante ha inoltre riportato due vendite precedenti negli ultimi tre mesi: 7.324 azioni vendute il 02/07/2025 per $13.055,76 e 26.048 azioni vendute l'15/08/2025 per $31.695,21. Il dichiarante certifica che non è noto alcuna informazione materiale avversa non disclosure.

Cardlytics, Inc. (CDLX) el aviso del Formulario 144 indica que un insider tiene la intención de vender 8,493 acciones comunes, con un valor de mercado agregado de $19,286.75, alrededor del 02/10/2025 a través de Fidelity Brokerage Services LLC en NASDAQ. Las acciones fueron adquiridas el 01/10/2025 por vesting de acciones restringidas como compensación. El presentante también reportó dos ventas previas en los últimos tres meses: 7,324 acciones vendidas el 02/07/2025 por $13,055.76 y 26,048 acciones vendidas el 15/08/2025 por $31,695.21. El presentante certifica que no se conoce información material adversa no revelada.

Cardlytics, Inc. (CDLX) Form 144 공지에 따르면 내부자가 8,493 주의 보통주를 $19,286.75의 총 시장가치로, 대략 2025년 10월 2일Fidelity Brokerage Services LLC를 통해 NASDAQ에서 매도하려는 의도를 가지고 있습니다. 이 주식은 2025년 10월 1일restricted stock vesting으로 보상으로 취득되었습니다. 신고자는 지난 3개월 동안 두 건의 이전 매도도 보고했습니다: 7,324 주가 2025년 7월 2일$13,055.76에 매도되었고, 26,048 주가 2025년 8월 15일$31,695.21에 매도되었습니다. 신고자는 공개되지 않은 중요한 악재 정보가 없다고 인증합니다.

Cardlytics, Inc. (CDLX) l'avis Form 144 indique qu'un initié a l'intention de vendre 8 493 actions ordinaires, d'une valeur marchande totale de $19 286,75, vers le 02/10/2025, par Fidelity Brokerage Services LLC, sur le NASDAQ. Les actions ont été acquises le 01/10/2025 par vesting d'actions restreintes en tant que rémunération. Le déclarant a également signalé deux ventes antérieures au cours des trois derniers mois : 7 324 actions vendues le 02/07/2025 pour $13 055,76 et 26 048 actions vendues le 15/08/2025 pour $31 695,21. Le déclarant certifie qu'aucune information matérielle adverse non divulgée n'est connue.

Cardlytics, Inc. (CDLX) Form 144 Hinweis zeigt, dass ein Insider beabsichtigt, 8.493 Stammaktien zu verkaufen, mit einem Gesamtmarktwert von $19.286,75, ungefähr am 02.10.2025 über Fidelity Brokerage Services LLC an der NASDAQ. Die Aktien wurden am 01.10.2025 durch Restricted Stock Vesting als Vergütung erworben. Der Einreicher meldete außerdem zwei vorherige Verkäufe in den letzten drei Monaten: 7.324 Aktien am 02.07.2025 für $13.055,76 und 26.048 Aktien am 15.08.2025 für $31.695,21. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Cardlytics (CDLX) disclose?

It discloses an intended sale of 8,493 common shares valued at $19,286.75 with an approximate sale date of 10/02/2025 via Fidelity Brokerage Services LLC on NASDAQ.

How were the 8,493 Cardlytics shares acquired?

The filing states the shares were acquired on 10/01/2025 through restricted stock vesting and the payment nature is listed as compensation.

Has the filer sold other Cardlytics shares recently?

Yes. The filer sold 7,324 shares on 07/02/2025 for $13,055.76 and 26,048 shares on 08/15/2025 for $31,695.21.

Who is the broker and where will the sale occur?

The broker is Fidelity Brokerage Services LLC and the sale is planned on the NASDAQ exchange.

Does the filer assert any undisclosed material information?

By signing the notice, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Cardlytics

NASDAQ:CDLX

CDLX Rankings

CDLX Latest News

CDLX Latest SEC Filings

CDLX Stock Data

126.17M
51.67M
2.95%
45.79%
14.27%
Advertising Agencies
Services-computer Programming, Data Processing, Etc.
Link
United States
ATLANTA